259 related articles for article (PubMed ID: 18771295)
1. Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation.
Wei Y; Li C; Huang W; Li B; Strome S; Wang LX
Biochemistry; 2008 Sep; 47(39):10294-304. PubMed ID: 18771295
[TBL] [Abstract][Full Text] [Related]
2. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
3. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
4. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.
Zou G; Ochiai H; Huang W; Yang Q; Li C; Wang LX
J Am Chem Soc; 2011 Nov; 133(46):18975-91. PubMed ID: 22004528
[TBL] [Abstract][Full Text] [Related]
5. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
Giddens JP; Wang LX
Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
[TBL] [Abstract][Full Text] [Related]
6. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.
Mimura Y; Katoh T; Saldova R; O'Flaherty R; Izumi T; Mimura-Kimura Y; Utsunomiya T; Mizukami Y; Yamamoto K; Matsumoto T; Rudd PM
Protein Cell; 2018 Jan; 9(1):47-62. PubMed ID: 28597152
[TBL] [Abstract][Full Text] [Related]
8. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
Front Immunol; 2017; 8():1554. PubMed ID: 29181010
[TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatic Defucosylation of Therapeutic Antibodies for Enhanced Effector Functions Using Bacterial α-Fucosidases.
Li C; Li T; Wang LX
Methods Mol Biol; 2018; 1827():367-380. PubMed ID: 30196507
[TBL] [Abstract][Full Text] [Related]
10. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
[TBL] [Abstract][Full Text] [Related]
11. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
12. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.
Liu CP; Tsai TI; Cheng T; Shivatare VS; Wu CY; Wu CY; Wong CH
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):720-725. PubMed ID: 29311294
[TBL] [Abstract][Full Text] [Related]
13. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.
Le NP; Bowden TA; Struwe WB; Crispin M
Biochim Biophys Acta; 2016 Aug; 1860(8):1655-68. PubMed ID: 27105835
[TBL] [Abstract][Full Text] [Related]
14. Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris.
Wang S; Rong Y; Wang Y; Kong D; Wang PG; Chen M; Kong Y
Microb Cell Fact; 2020 Jan; 19(1):7. PubMed ID: 31931833
[TBL] [Abstract][Full Text] [Related]
15. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
16. Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation.
Yang Q; An Y; Zhu S; Zhang R; Loke CM; Cipollo JF; Wang LX
ACS Chem Biol; 2017 Jun; 12(6):1665-1673. PubMed ID: 28452462
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
18. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
Mimura Y; Church S; Ghirlando R; Ashton PR; Dong S; Goodall M; Lund J; Jefferis R
Mol Immunol; 2000; 37(12-13):697-706. PubMed ID: 11275255
[TBL] [Abstract][Full Text] [Related]
19. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of deglycosylated human IgG4-Fc.
Davies AM; Jefferis R; Sutton BJ
Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
